{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:35:00Z","timestamp":1790087700711,"version":"4.0.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education","award":["2017R1D1A1B03033382"],"award-info":[{"award-number":["2017R1D1A1B03033382"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-018-0799-4","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T03:51:50Z","timestamp":1543981910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-9736","authenticated-orcid":false,"given":"Jinkwon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5585-7739","authenticated-orcid":false,"given":"Kyung-Yul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"issue":"Suppl 1","key":"799_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2165\/1158822-S0-000000000-00000","volume":"10","author":"TR Pedersen","year":"2010","unstructured":"Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(Suppl 1):10\u20137.","journal-title":"Am J Cardiovasc Drugs."},{"key":"799_CR2","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.","journal-title":"Cochrane Database Syst Rev."},{"key":"799_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735\u201342.","journal-title":"Lancet"},{"key":"799_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565\u201371.","journal-title":"Lancet"},{"key":"799_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.numecd.2017.03.001","volume":"27","author":"M Casula","year":"2017","unstructured":"Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27:396\u2013406.","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"799_CR6","doi-asserted-by":"publisher","first-page":"i5953","DOI":"10.1136\/bmj.i5953","volume":"355","author":"Y Huang","year":"2016","unstructured":"Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.","journal-title":"BMJ"},{"key":"799_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jacc.2009.10.060","volume":"55","author":"ES Ford","year":"2010","unstructured":"Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"799_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1475-2840-10-63","volume":"10","author":"M Biteker","year":"2011","unstructured":"Biteker M, Dayan A, Can MM, \u0130lhan E, Biteker FS, Tekke\u015fin A, et al. Impaired fasting glucose is associated with increased perioperative cardiovascular event rates in patients undergoing major non-cardiothoracic surgery. Cardiovasc Diabetol. 2011;10:63.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cpt.274","volume":"99","author":"U Anyanwagu","year":"2016","unstructured":"Anyanwagu U, Idris I, Donnelly R. Drug-induced diabetes mellitus: evidence for statins and other drugs affecting glucose metabolism. Clin Pharmacol Ther. 2016;99:390\u2013400.","journal-title":"Clin Pharmacol Ther"},{"key":"799_CR10","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1210\/jc.2013-2674","volume":"98","author":"J Puurunen","year":"2013","unstructured":"Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013;98:4798\u2013807.","journal-title":"J Clin Endocrinol Metab"},{"key":"799_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12933-014-0111-1","volume":"13","author":"L-Y Lin","year":"2014","unstructured":"Lin L-Y, Huang C-C, Chen J-S, Wu T-C, Leu H-B, Huang P-H, et al. Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study. Cardiovasc Diabetol. 2014;13:111.","journal-title":"Cardiovasc Diabetol."},{"issue":"Suppl 1","key":"799_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1475-2840-12-S1-S1","volume":"12","author":"H Ginsberg","year":"2013","unstructured":"Ginsberg H. Statins in cardiometabolic disease: what makes pitavastatin different? Cardiovasc Diabetol. 2013;12(Suppl 1):S1.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR13","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.2147\/DDDT.S87979","volume":"9","author":"W Zhao","year":"2015","unstructured":"Zhao W, Zhao S-P. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des Dev Ther. 2015;9:6211\u201323.","journal-title":"Drug Des Dev Ther."},{"key":"799_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40256-016-0197-9","volume":"17","author":"J Mill\u00e1n N\u00fa\u00f1ez-Cort\u00e9s","year":"2017","unstructured":"Mill\u00e1n N\u00fa\u00f1ez-Cort\u00e9s J, Cases Amen\u00f3s A, Ascaso Gimilio JF, Barrios Alonso V, Pascual Fuster V, Pedro-Botet Montoya JC, et al. Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA Study. Am J Cardiovasc Drugs. 2017;17:135\u201342.","journal-title":"Am J Cardiovasc Drugs."},{"key":"799_CR15","doi-asserted-by":"publisher","first-page":"e016640","DOI":"10.1136\/bmjopen-2017-016640","volume":"7","author":"SC Seong","year":"2017","unstructured":"Seong SC, Kim Y-Y, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7:e016640.","journal-title":"BMJ Open"},{"key":"799_CR16","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","volume":"373","author":"AG Tab\u00e1k","year":"2009","unstructured":"Tab\u00e1k AG, Jokela M, Akbaraly TN, Brunner EJ, Kivim\u00e4ki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215\u201321.","journal-title":"Lancet"},{"key":"799_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4239\/wjd.v6.i2.352","volume":"6","author":"B Chogtu","year":"2015","unstructured":"Chogtu B, Magazine R, Bairy K. Statin use and risk of diabetes mellitus. World J Diabetes. 2015;6:352\u20137.","journal-title":"World J Diabetes."},{"key":"799_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1758-5996-6-53","volume":"6","author":"SM Liew","year":"2014","unstructured":"Liew SM, Lee PY, Hanafi NS, Ng CJ, Wong SSL, Chia YC, et al. Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes. Diabetol Metab Syndr. 2014;6:53.","journal-title":"Diabetol Metab Syndr."},{"key":"799_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s11883-014-0472-7","volume":"17","author":"DC Chan","year":"2015","unstructured":"Chan DC, Pang J, Watts GF. Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10? Curr Atheroscler Rep. 2015;17:472.","journal-title":"Curr Atheroscler Rep."},{"key":"799_CR20","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1056\/NEJMp1203020","volume":"366","author":"AB Goldfine","year":"2012","unstructured":"Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366:1752\u20135.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"799_CR21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1475-2840-12-S1-S3","volume":"12","author":"K Ray","year":"2013","unstructured":"Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol. 2013;12(Suppl 1):S3.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-017-0587-6","volume":"16","author":"U Anyanwagu","year":"2017","unstructured":"Anyanwagu U, Mamza J, Donnelly R, Idris I. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study. Cardiovasc Diabetol. 2017;16:107.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/2040622315596118","volume":"6","author":"A Kei","year":"2015","unstructured":"Kei A, Rizos EC, Elisaf M. Statin use in prediabetic patients: rationale and results to date. Ther Adv Chronic Dis. 2015;6:246\u201351.","journal-title":"Ther Adv Chronic Dis."},{"key":"799_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1475-2840-8-25","volume":"8","author":"HK Berthold","year":"2009","unstructured":"Berthold HK, Gouni-Berthold I, B\u00f6hm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8:25.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-015-0318-9","volume":"15","author":"JW Bai","year":"2016","unstructured":"Bai JW, Boulet G, Halpern EM, Lovblom LE, Eldelekli D, Keenan HA, et al. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovasc Diabetol. 2016;15:14.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12933-017-0548-0","volume":"16","author":"M Hanefeld","year":"2017","unstructured":"Hanefeld M, Traylor L, Gao L, Landgraf W. The use of lipid-lowering therapy and effects of antihyperglycemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100\u00a0U\/mL. Cardiovasc Diabetol. 2017;16:66.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2840-8-26","volume":"8","author":"PP Toth","year":"2009","unstructured":"Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis. Cardiovasc Diabetol. 2009;8:26.","journal-title":"Cardiovasc Diabetol."},{"key":"799_CR28","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","volume":"57","author":"S Erqou","year":"2014","unstructured":"Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57:2444\u201352.","journal-title":"Diabetologia"},{"key":"799_CR29","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2337\/dc18-Srev01","volume":"41","author":"Summary of Revisions","year":"2018","unstructured":"Summary of Revisions. Standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S4\u20136.","journal-title":"Diabetes Care"},{"key":"799_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/M17-0681","volume":"168","author":"MB Mortensen","year":"2018","unstructured":"Mortensen MB, Nordestgaard BG. Comparison of five major guidelines for statin use in primary prevention in a contemporary general population. Ann Intern Med. 2018;168:85\u201392.","journal-title":"Ann Intern Med"},{"key":"799_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373\u2013418.","journal-title":"Am J Cardiovasc Drugs."},{"key":"799_CR32","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc11-s207","volume":"34","author":"F Pistrosch","year":"2011","unstructured":"Pistrosch F, Natali A, Hanefeld M. Is hyperglycemia a cardiovascular risk factor? Diabetes Care. 2011;34:S128\u201331.","journal-title":"Diabetes Care"},{"key":"799_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2014.04.001","volume":"15","author":"NA Sattar","year":"2014","unstructured":"Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014;15:1\u201315.","journal-title":"Atheroscler Suppl."},{"issue":"61","key":"799_CR34","first-page":"375","volume":"2015","author":"A Bernardi","year":"1992","unstructured":"Bernardi A, Rocha VZ, Faria-Neto JR. Use of statins and the incidence of type 2 diabetes mellitus. Rev Assoc Med Bras. 1992;2015(61):375\u201380.","journal-title":"Rev Assoc Med Bras"},{"key":"799_CR35","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","volume":"8","author":"KC Maki","year":"2014","unstructured":"Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. The Diabetes Subpanel of the National Lipid Association Expert Panel null. An assessment by the Statin Diabetes Safety Task Force 2014 update. J Clin Lipidol. 2014;8:S17\u201329.","journal-title":"J Clin Lipidol."},{"key":"799_CR36","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s00125-014-3409-3","volume":"57","author":"DI Swerdlow","year":"2014","unstructured":"Swerdlow DI, Sattar N. A dysglycaemic effect of statins in diabetes: relevance to clinical practice? Diabetologia. 2014;57:2433\u20135.","journal-title":"Diabetologia"},{"key":"799_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/157339910793499092","volume":"6","author":"GN Thomas","year":"2010","unstructured":"Thomas GN, Jiang CQ, Taheri S, Xiao ZH, Tomlinson B, Cheung BMY, et al. A systematic review of lifestyle modification and glucose intolerance in the prevention of type 2 diabetes. Curr Diabetes Rev. 2010;6:378\u201387.","journal-title":"Curr Diabetes Rev"},{"key":"799_CR38","doi-asserted-by":"publisher","first-page":"f6745","DOI":"10.1136\/bmj.f6745","volume":"347","author":"L Shen","year":"2013","unstructured":"Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, et al. Role of diuretics, \u03b2 blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347:f6745.","journal-title":"BMJ"},{"key":"799_CR39","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40264-015-0339-z","volume":"38","author":"N Fathallah","year":"2015","unstructured":"Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38:1153\u201368.","journal-title":"Drug Saf"},{"key":"799_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4093\/dmj.2015.39.5.353","volume":"39","author":"KG Parhofer","year":"2015","unstructured":"Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J. 2015;39:353\u201362.","journal-title":"Diabetes Metab J."},{"key":"799_CR41","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144\u201353.","journal-title":"N Engl J Med"},{"key":"799_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2017;5:97\u2013105.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"799_CR43","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316:1383\u201391.","journal-title":"JAMA"},{"key":"799_CR44","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2015.1206","volume":"313","author":"J Besseling","year":"2015","unstructured":"Besseling J, Kastelein JJP, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313:1029\u201336.","journal-title":"JAMA"},{"key":"799_CR45","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/bmjdrc-2014-000017","volume":"2","author":"D Nowis","year":"2014","unstructured":"Nowis D, Malenda A, Furs K, Oleszczak B, Sadowski R, Chlebowska J, et al. Statins impair glucose uptake in human cells. BMJ Open Diabetes Res Care. 2014;2:e000017.","journal-title":"BMJ Open Diabetes Res Care."},{"key":"799_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","volume":"26","author":"UK Sampson","year":"2011","unstructured":"Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26:342\u20137.","journal-title":"Curr Opin Cardiol"},{"key":"799_CR47","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","volume":"49","author":"M Nakata","year":"2006","unstructured":"Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49:1881\u201392.","journal-title":"Diabetologia"},{"key":"799_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5551\/jat.12.111","volume":"12","author":"H Mabuchi","year":"2005","unstructured":"Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005;12:111\u20139.","journal-title":"J Atheroscler Thromb."},{"key":"799_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1567-5688(14)70002-9","volume":"16","author":"L Arnaboldi","year":"2015","unstructured":"Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015;16:1\u201327.","journal-title":"Atheroscler Suppl."},{"key":"799_CR50","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012\u201322.","journal-title":"Eur Heart J."},{"key":"799_CR51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","volume":"40","author":"BA Parker","year":"2012","unstructured":"Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40:188\u201394.","journal-title":"Exerc Sport Sci Rev"},{"key":"799_CR52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597\u2013603.","journal-title":"Am Heart J"},{"key":"799_CR53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/HCO.0000000000000317","volume":"31","author":"GA Panza","year":"2016","unstructured":"Panza GA, Taylor BA, Thompson PD. An update on the relationship between statins and physical activity. Curr Opin Cardiol. 2016;31:572\u20139.","journal-title":"Curr Opin Cardiol"},{"key":"799_CR54","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"799_CR55","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","volume":"172","author":"AL Culver","year":"2012","unstructured":"Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women\u2019s Health Initiative. Arch Intern Med. 2012;172:144\u201352.","journal-title":"Arch Intern Med"},{"key":"799_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/MOL.0000000000000172","volume":"26","author":"JG Robinson","year":"2015","unstructured":"Robinson JG. Statins and diabetes risk: how real is it and what are the mechanisms? Curr Opin Lipidol. 2015;26:228\u201335.","journal-title":"Curr Opin Lipidol"},{"key":"799_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2015.194","volume":"12","author":"DJ Betteridge","year":"2016","unstructured":"Betteridge DJ, Carmena R. The diabetogenic action of statins\u2014mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12:99\u2013110.","journal-title":"Nat Rev Endocrinol."},{"key":"799_CR58","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","volume":"111","author":"EP Navarese","year":"2013","unstructured":"Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123\u201330.","journal-title":"Am J Cardiol"},{"key":"799_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","volume":"103","author":"DJ Freeman","year":"2001","unstructured":"Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357\u201362.","journal-title":"Circulation"},{"key":"799_CR60","doi-asserted-by":"publisher","first-page":"f2610","DOI":"10.1136\/bmj.f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.","journal-title":"BMJ"},{"key":"799_CR61","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/TCRM.S117150","volume":"12","author":"J Lee","year":"2016","unstructured":"Lee J, Noh Y, Shin S, Lim H-S, Park RW, Bae SK, et al. Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag. 2016;12:1533\u201343.","journal-title":"Ther Clin Risk Manag"},{"key":"799_CR62","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.atherosclerosis.2006.08.023","volume":"194","author":"S Sugiyama","year":"2007","unstructured":"Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis. 2007;194:e43\u201351.","journal-title":"Atherosclerosis."},{"key":"799_CR63","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","volume":"126","author":"T Yada","year":"1999","unstructured":"Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999;126:1205\u201313.","journal-title":"Br J Pharmacol"},{"key":"799_CR64","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623\u201330.","journal-title":"Lancet"},{"key":"799_CR65","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3466.2003.tb00116.x","volume":"21","author":"K Kajinami","year":"2003","unstructured":"Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21:199\u2013215.","journal-title":"Cardiovasc Drug Rev"},{"key":"799_CR66","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","volume":"241","author":"AJ Vallejo-Vaz","year":"2015","unstructured":"Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, Michishita I, Nozue T, Sugiyama S, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241:409\u201318.","journal-title":"Atherosclerosis."},{"key":"799_CR67","unstructured":"Odawara M, Yamazaki T, Kishimoto J, Ito C, Noda M, Terauchi Y, et al. Pitavastatin for the delay or prevention of diabetes development in individuals with impaired glucose tolerance. In: 73th American Diabetes Association Annual Meeting. 2013."},{"key":"799_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jdi.12483","volume":"7","author":"CH Huang","year":"2016","unstructured":"Huang CH, Huang YY, Hsu BRS. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016;7:769\u201376.","journal-title":"J Diabetes Investig."},{"key":"799_CR69","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.metabol.2014.09.008","volume":"64","author":"Y Cho","year":"2015","unstructured":"Cho Y, Choe E, Lee Y-H, Seo JW, Choi Y, Yun Y, et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metab Clin Exp. 2015;64:482\u20138.","journal-title":"Metab Clin Exp"},{"key":"799_CR70","doi-asserted-by":"publisher","first-page":"E1659","DOI":"10.1016\/S0735-1097(12)61660-X","volume":"59","author":"V Kryzhanovski","year":"2012","unstructured":"Kryzhanovski V, Eriksson M, Hounslow N, Sponseller C. Short-term and long-term effects of pitavastatin and simvastatin on fasting plasma glucose in patients with primary hyperlipidemia or mixed dyslipidemia and\u2009\u2265\u20092 risk factors for coronary heart disease. J Am Coll Cardiol. 2012;59:E1659.","journal-title":"J Am Coll Cardiol"},{"key":"799_CR71","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s00125-017-4275-6","volume":"60","author":"A Hulman","year":"2017","unstructured":"Hulman A, Simmons RK, Brunner EJ, Witte DR, F\u00e6rch K, Vistisen D, et al. Trajectories of glycaemia, insulin sensitivity and insulin secretion in South Asian and white individuals before diagnosis of type 2 diabetes: a longitudinal analysis from the Whitehall II cohort study. Diabetologia. 2017;60:1252\u201360.","journal-title":"Diabetologia"},{"key":"799_CR72","first-page":"685","volume":"22","author":"I Lin","year":"2016","unstructured":"Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22:685\u201398.","journal-title":"J Manag Care Spec Pharm."},{"key":"799_CR73","first-page":"685","volume":"3","author":"JK Lee","year":"2007","unstructured":"Lee JK, Grace KA, Foster TG, Crawley MJ, Erowele GI, Sun HJ, et al. How should we measure medication adherence in clinical trials and practice? Ther Clin Risk Manag. 2007;3:685\u201390.","journal-title":"Ther Clin Risk Manag"},{"key":"799_CR74","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/00005650-199909000-00002","volume":"37","author":"PW Choo","year":"1999","unstructured":"Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999;37:846\u201357.","journal-title":"Med Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-018-0799-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T15:53:38Z","timestamp":1605542018000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0799-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0799-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"20 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"155"}}